Company intelligence / Profile preview
Quell Therapeutics
London, England, United Kingdomquell-tx.com ↗
- Ownership
- Private
- Employees
- ~125
- Development stage
- Phase 1
01
Overview
Quell Therapeutics has demonstrated leadership in the field of engineered regulatory T cell therapies. Its lead candidate QEL‑001 aims to induce operational tolerance after liver transplantation, potentially reducing or eliminating the need for chronic immunosuppression. The company has also entered a major partnership with AstraZeneca to develop autologous engineered Treg therapies for Type 1 Diabetes and Inflammatory Bowel Disease. Clinical results are still emerging as programs advance through early-stage trials.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Engineered regulatory T cells (Tregs)cell therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
AstraZeneca – exclusive option and license agreement for autoimmune disease cell therapy development ($85M upfront plus milestones/royalties)King’s College LondonUniversity College LondonUniversity Health NetworkHannover Medical SchoolUniversity of FloridaUniversity of Pittsburgh
Beyond the preview
Go deeper on Quell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quell Therapeutics.